Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Zynerba Pharmaceuticals, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Zynerba Pharmaceuticals, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Zynerba Pharmaceuticals, Inc. since 2005.
The reporting company's ticker symbol is ZYNE. The reporting company's CIK number is 1621443.
The total value of stock buying since 2005 is $687,409.
The total value of stock sales since 2005 is $31,589.
The total value of stock option exercises since 2005 is $63,508.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2017-05-15||Anido Armando (Chairman & Chief Exec. Officer)||Buy||1,500||19.57||29,355|
|2017-05-12||Fickenscher James E (Chief Financial Officer)||Buy||5,200||19.82||103,064|
|2017-05-12||Anido Armando (Chairman & Chief Exec. Officer)||Buy||3,500||19.76||69,160|
|2016-12-07||Fickenscher James E (Chief Financial Officer)||Buy||4,000||14.03||56,120|
|2016-12-06||Fickenscher James E (Chief Financial Officer)||Buy||3,000||14.15||42,450|
|2016-08-16||Hanlon Suzanne M. (Sec, General Counsel & VP HR)||Sale||3,000||10.53||31,589|
|2015-09-11||Baron Richard A (Chief Financial Officer)||Option Ex||15,957||3.98||63,508|
|2015-08-10||Harrison Thomas L (Director)||Buy||12,500||14.00||175,000|
|2015-08-05||Hanlon Suzanne M. (Sec, General Counsel & VP HR)||Buy||3,000||17.92||53,760|
Insider trading activities including stock purchases, stock sales, and option exercises of ZYNE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Zynerba Pharmaceuticals, Inc. (symbol ZYNE, CIK number 1621443) see the Securities and Exchange Commission (SEC) website.